Cited 0 time in
Inhibition of GSK-3 reduces infarct volume and improves neurobehavioral functions
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Koh, Seong-Ho | - |
| dc.contributor.author | Yoo, A. Rum | - |
| dc.contributor.author | Chang, Dae-Il | - |
| dc.contributor.author | Hwang, Se J. | - |
| dc.contributor.author | Kim, Seung H. | - |
| dc.date.accessioned | 2022-10-07T10:16:25Z | - |
| dc.date.available | 2022-10-07T10:16:25Z | - |
| dc.date.issued | 2008-07 | - |
| dc.identifier.issn | 0006-291X | - |
| dc.identifier.issn | 1090-2104 | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/171991 | - |
| dc.description.abstract | In the present study, we have investigated the effects of glycogen synthase kinase-3 (GSK-3) inhibition on infarct volume and neurobehavioral functions in a focal cerebral ischemia model. To achieve our goals, GSK-3 inhibitor II or VIII was injected at several time points and in varing dosages. GSK-3 inhibitor VIII was more effective than inhibitor II, and infarct volume and water content in the VIII group were significantly decreased 24 h after the onset of ischemic stroke, as compared with the control group, These protective effects were associated with reductions of TUNEL-positive cells, neutrophil infiltration, glucose levels after ischemia, and GSK-3 enzyme activity. In addition, expressions of death and inflammation-related signals decreased and those of survival-related signals increased. Lastly, neurobehavioral functions were restored to a greater extent in the VIII group than in the control group. Together, these results suggest that GSK-3 inhibition reduces infarct volume and restores neurobehavioral functions. | - |
| dc.format.extent | 6 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | Academic Press | - |
| dc.title | Inhibition of GSK-3 reduces infarct volume and improves neurobehavioral functions | - |
| dc.type | Article | - |
| dc.publisher.location | 미국 | - |
| dc.identifier.doi | 10.1016/j.bbrc.2008.05.006 | - |
| dc.identifier.scopusid | 2-s2.0-44149110850 | - |
| dc.identifier.wosid | 000256506600061 | - |
| dc.identifier.bibliographicCitation | Biochemical and Biophysical Research Communications, v.371, no.4, pp 894 - 899 | - |
| dc.citation.title | Biochemical and Biophysical Research Communications | - |
| dc.citation.volume | 371 | - |
| dc.citation.number | 4 | - |
| dc.citation.startPage | 894 | - |
| dc.citation.endPage | 899 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
| dc.relation.journalResearchArea | Biophysics | - |
| dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
| dc.relation.journalWebOfScienceCategory | Biophysics | - |
| dc.subject.keywordPlus | GLYCOGEN-SYNTHASE KINASE-3 | - |
| dc.subject.keywordPlus | CEREBRAL-ARTERY OCCLUSION | - |
| dc.subject.keywordPlus | PARP INHIBITOR | - |
| dc.subject.keywordPlus | BRAIN | - |
| dc.subject.keywordPlus | DEATH | - |
| dc.subject.keywordPlus | ISCHEMIA | - |
| dc.subject.keywordPlus | ROLES | - |
| dc.subject.keywordPlus | RATS | - |
| dc.subject.keywordAuthor | glycogen synthase kinase-3 | - |
| dc.subject.keywordAuthor | ischemia | - |
| dc.subject.keywordAuthor | stroke | - |
| dc.subject.keywordAuthor | inflammation | - |
| dc.subject.keywordAuthor | neuronal cell death | - |
| dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0006291X08009029?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
